Cogent Biosciences Inc (COGT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cogent Biosciences Inc (COGT) has a cash flow conversion efficiency ratio of -0.124x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-79.11 Million) by net assets ($636.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cogent Biosciences Inc (COGT) total market value for the company's overall valuation and market capitalisation.
Cogent Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Cogent Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Cogent Biosciences Inc for real-time trading data and today's change.
Cogent Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cogent Biosciences Inc ranked by their cash flow conversion efficiency. Review COGT FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Parkland Fuel Corporation
TO:PKI
|
0.158x |
|
Pampa Energia SA
BA:PAMP
|
0.053x |
|
Maase Inc.
NASDAQ:MAAS
|
-0.009x |
|
Compagnie Generale des Etablissements Michelin SCA
LSE:0OFM
|
0.069x |
|
Iridium Communications Inc
NASDAQ:IRDM
|
0.242x |
|
APT Medical Inc
SHG:688617
|
0.098x |
|
LS Corp
KO:006260
|
0.078x |
|
EPAM Systems Inc
NYSE:EPAM
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Cogent Biosciences Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Cogent Biosciences Inc from 2015 to 2025. Also see Cogent Biosciences Inc balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $636.37 Million | $-264.44 Million | -0.416x | +48.75% |
| 2024-12-31 | $256.29 Million | $-207.79 Million | -0.811x | -36.06% |
| 2023-12-31 | $257.80 Million | $-153.62 Million | -0.596x | -28.45% |
| 2022-12-31 | $255.74 Million | $-118.64 Million | -0.464x | -69.09% |
| 2021-12-31 | $214.18 Million | $-58.76 Million | -0.274x | -79.59% |
| 2020-12-31 | $234.67 Million | $-35.85 Million | -0.153x | +88.31% |
| 2019-12-31 | $31.76 Million | $-41.51 Million | -1.307x | -142.32% |
| 2018-12-31 | $60.23 Million | $-32.49 Million | -0.539x | +40.91% |
| 2017-12-31 | $28.30 Million | $-25.84 Million | -0.913x | -156.53% |
| 2016-12-31 | $52.39 Million | $-18.64 Million | -0.356x | -239.62% |
| 2015-12-31 | $69.52 Million | $17.72 Million | 0.255x | -- |
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well… Read more